IRON Quote, Financials, Valuation and Earnings

Innoviva has a net margin of -- compared to Disc Medicine's net margin of 22.15%. Disc Medicine's return on equity of -- beat Innoviva's return on equity of 3.44%.

Disc Medicine has a consensus price target of $98.40, signalling upside risk potential of 154.07%. On the other hand Innoviva has an analysts' consensus of $19.00 which suggests that it could grow by 8.45%. Given that Disc Medicine has higher upside potential than Innoviva, analysts believe Disc Medicine is more attractive than Innoviva.

Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innoviva has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.553%.

Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

Disc Medicine quarterly revenues are --, which are smaller than Innoviva quarterly revenues of $91.8M. Disc Medicine's net income of -$29.5M is lower than Innoviva's net income of $20.3M. Notably, Disc Medicine's price-to-earnings ratio is -- while Innoviva's PE ratio is 92.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 3.88x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Disc Medicine's net margin of -49.65%. Disc Medicine's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Disc Medicine has a consensus price target of $98.40, signalling upside risk potential of 154.07%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that Disc Medicine has higher upside potential than NovaBay Pharmaceuticals, analysts believe Disc Medicine is more attractive than NovaBay Pharmaceuticals.

Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Disc Medicine quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Disc Medicine's net income of -$29.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Disc Medicine's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Disc Medicine's net margin of -2357.27%. Disc Medicine's return on equity of -- beat Palatin Technologies's return on equity of --.

Disc Medicine has a consensus price target of $98.40, signalling upside risk potential of 154.07%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Disc Medicine, analysts believe Palatin Technologies is more attractive than Disc Medicine.

Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Disc Medicine quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Disc Medicine's net income of -$29.5M is lower than Palatin Technologies's net income of -$2.4M. Notably, Disc Medicine's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Disc Medicine's net margin of -18.58%. Disc Medicine's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Disc Medicine has a consensus price target of $98.40, signalling upside risk potential of 154.07%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Disc Medicine has higher upside potential than Retractable Technologies, analysts believe Disc Medicine is more attractive than Retractable Technologies.

Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Disc Medicine quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Disc Medicine's net income of -$29.5M is lower than Retractable Technologies's net income of -$1.9M. Notably, Disc Medicine's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.